Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia Wemeau M; Kepp O; Tesniere A; Panaretakis T; Flament C; De Botton S; Zitvogel L; Kroemer G; Chaput NCell Death Dis 2010[Dec]; 1 (12): e104Experiments performed in mice revealed that anthracyclines stimulate immunogenic cell death that is characterized by the pre-apoptotic exposure of calreticulin (CRT) on the surface of dying tumor cells. Here, we determined whether CRT exposure at the cell surface (ecto-CRT) occurs in human cancer in response to anthracyclines in vivo, focusing on acute myeloid leukemia (AML), which is currently treated with a combination of aracytine and anthracyclines. Most of the patients benefit from the induction chemotherapy but relapse within 1-12 months. In this study, we investigated ecto-CRT expression on malignant blasts before and after induction chemotherapy. We observed that leukemic cells from some patients exhibited ecto-CRT regardless of chemotherapy and that this parameter was not modulated by in vivo chemotherapy. Ecto-CRT correlated with the presence of phosphorylated eIF2alpha within the blasts, in line with the possibility that CRT exposure results from an endoplasmic reticulum stress response. Importantly, high levels of ecto-CRT on malignant myeloblasts positively correlated with the ability of autologous T cells to secrete interferon-gamma on stimulation with blast-derived dendritic cell. We conclude that the presence of ecto-CRT on leukemia cells facilitates cellular anticancer immune responses in AML patients.|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Anthracyclines/*therapeutic use[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Calreticulin/drug effects/*metabolism[MESH]|Cohort Studies[MESH]|Dendritic Cells/physiology[MESH]|Eukaryotic Initiation Factor-2/metabolism[MESH]|Female[MESH]|Humans[MESH]|Immunity, Cellular/drug effects[MESH]|Leukemia, Myeloid, Acute/*drug therapy/immunology/metabolism/pathology[MESH]|Male[MESH]|Middle Aged[MESH]|Phagocytosis/drug effects[MESH]|Phosphorylation[MESH]|Survival Analysis[MESH]|T-Lymphocytes/immunology[MESH] |